about
Molecular Imaging of Biomarkers in Breast CancerMusculoskeletal tumours and tumour-like conditions: common and avoidable pitfalls at imaging in patients with known or suspected cancer: Part B: malignant mimics of benign tumoursThe Impact That Number of Analyzed Metastatic Breast Cancer Lesions Has on Response Assessment by 18F-FDG PET/CT Using PERCISTRetrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years.Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma.A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation.Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma.Detection of Internal Mammary Adenopathy in Patients With Breast Cancer by PET/CT and MRI.Comparison of the effectiveness of MRI perfusion and fluorine-18 FDG PET-CT for differentiating radiation injury from viable brain tumor: a preliminary retrospective analysis with pathologic correlation in all patientsPrognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma.Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CTIdentifying and distinguishing treatment effects and complications from malignancy at FDG PET/CT.Is methylene diphosphonate bone scan necessary for initial staging of Ewing sarcoma if 18F-FDG PET/CT is performed?(18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancerMetabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 1.0.FDG PET/CT Assesses the Risk of Femoral Pathological Fractures in Patients With Metastatic Breast Cancer.Value of second-opinion review of outside institution PET-CT examinations.18F-FDG-PET/CT for systemic staging of patients with newly diagnosed ER-positive and HER2-positive breast cancer.Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers.Hill-Sachs lesion on FDG PET/CT.Focused regional FDG PET/CT detects more osseous metastases than does whole-body PET/CT.FDG-avid venous malformation could mimic malignancy on 18F-FDG PET/CT.FDG-Avid Intrathecal Inflammation Following Administration of Intrathecal Methotrexate.False-positive FDG PET/CT due to liver parenchymal injury caused by a surgical retractor.Predictive Value of Positron Emission Tomography/Computed Tomography to Assess Early Treatment Response to Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade Without Chemotherapy for HER2-Positive Metastatic Breast Cancer: Are We Ready toFDG PET/CT findings in a rare case of giant fibrovascular polyp of the esophagus harboring atypical lipomatous tumor/well-differentiated liposarcoma.False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma.Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer.FDG PET/CT demonstration of right atrium metastasis overlooked on contrast-enhanced CT.Reply: Breast Cancer Staging: To Which Women Should 18F-FDG PET/CT Be Offered?Ipilimumab-induced colitis on FDG PET/CTBreast implant foreign body reaction mimicking breast cancer recurrence on FDG PET/CTUnilateral Suppression of Brown Fat on FDG PET/CT in Horner SyndromeCD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human ImagingThe QIBA Profile for FDG PET/CT: Improving the Value of PETIdentification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted 89Zr-Pertuzumab PET/CT
P50
Q26772870-53154051-021A-48A2-880A-4C05BB35AB72Q26865396-3B8A0AD7-9AAE-4A87-B4E2-65A2C3FA7D08Q33860281-D210625A-28B4-4E37-AD22-090A5DF6B9E7Q35552138-EC2616F4-4586-4A17-9BEF-21982A7D7044Q36219679-7B0743BD-CBA5-4872-9EF3-7CE01C28C583Q36893250-340D6036-9B5A-47DA-83C2-1E20BD8D2900Q36908141-64EB995A-05C9-44E5-A1B3-CD14D26C9863Q37146074-383D13EF-28B5-4A37-8146-862302EAA69CQ37212449-6DE9DA51-A101-4A8E-9291-E79BA56C6393Q37221563-79F0F22B-8DC0-44E6-846D-2777F5AD3D87Q37309906-83DB3F7E-71AA-4F30-BA70-F42829D44651Q38151050-7B7F4060-C0D4-4C52-A9CC-C9820600D1ABQ38198713-6EE162B7-CA4D-4BD7-B4E7-5FF635888CC4Q38821174-B41E476D-C7EB-4BA5-97F6-A8E5F0207B0AQ38830196-259615B5-F10D-41BE-8EA5-DD605C7B4538Q39122509-FFDA79C6-ECB0-4FC2-A4FE-6BCB4D3DB248Q39177634-B4CC2CA8-926D-4951-8EFB-F5A0FA361DE9Q39272681-8520A49A-198E-4A71-903B-083998A734DAQ40872960-FD5451C6-F326-411E-879F-304AD85E7104Q44681972-93FAEF01-09CD-4D00-BE03-BCB563CA9680Q46188307-D3B32630-4EB0-48C6-9B36-87729171A842Q46362970-39E8909C-384C-4378-BB3F-69F0374F8C35Q47136604-8F8AE365-87B0-49B9-A8CB-D601EE80C38CQ49100803-DDF93462-A414-4035-80C0-133683F62E42Q50953005-6263DCFD-CE76-4FD3-BAEC-239A6F72B396Q53082270-38D04289-EB55-4DFB-A9B6-C270D9E15F16Q53088475-9917E7F6-F0B0-40D8-8CE9-BCBB07719992Q53165455-45E5EC44-C9D5-4BBC-BE47-02156A388695Q53233214-B8502528-6368-4317-947A-53326AA714C5Q53718482-68292552-CC6D-4EDB-B0DD-8B1B498AF227Q84188173-6F801A62-06C1-414C-90ED-F0CCE1377A4BQ86707603-812EC7EA-EC78-4E5E-917C-A6BC176ACA39Q87994445-EDEC247C-F195-4020-8F9B-4FF9B6B21059Q91627443-4E7F1F17-049F-4344-9589-581332A978A3Q92471143-950068FF-ED6D-4600-9E5B-F0C8FC804753Q96222104-2468C9F4-2E0B-456A-8D49-03D23F161374
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Gary A Ulaner
@ast
Gary A Ulaner
@en
Gary A Ulaner
@es
Gary A Ulaner
@nl
Gary A Ulaner
@sl
type
label
Gary A Ulaner
@ast
Gary A Ulaner
@en
Gary A Ulaner
@es
Gary A Ulaner
@nl
Gary A Ulaner
@sl
prefLabel
Gary A Ulaner
@ast
Gary A Ulaner
@en
Gary A Ulaner
@es
Gary A Ulaner
@nl
Gary A Ulaner
@sl
P106
P21
P31
P496
0000-0002-7953-0113